The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US EPA approves Byotrol24 as long-lasting virucide

24 May 2023 15:14

RNS Number : 5499A
Byotrol PLC
24 May 2023
 

 

 

 

 

Byotrol Plc

 

("Byotrol" or the "Company")

 

EPA approval for

long-lasting performance against viruses

 

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, is pleased to announce that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. 

 

The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). 

The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy.

 David Traynor, Executive Director, Byotrol plc comments:

 "This is fantastic news for Byotrol and confirms the excellence of our US surface sanitizers. 

Customers and consumers are now as concerned about protecting against viruses as well as bacteria. This new approval means we can now make specific long-lasting efficacy claims against viruses, which should in turn significantly increase the commercial potential of our US formulations."

 

 

For further information contact:

 

Byotrol Plc

David Traynor, Executive Director

Dr Trevor Francis, Non- Executive Chairman

+44 (0)1925 742 000

Vivan Pinto, Chief Executive Officer

Chris Sedwell, Chief Financial Officer

 

finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/George Dollemore - Corporate Finance

Nigel Birks/Harriet Ward - ECM

Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

byotrol@flagstaffcomms.com

 

 

 

 

 

This announcement is released by Byotrol Plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, go to byotrol.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUSASROUUVUAR
Date   Source Headline
5th Aug 20097:00 amRNSUpdate on current business
30th Jul 20094:46 pmRNSResult of AGM
9th Jul 20098:07 amRNSAnnual Report & Accounts
30th Jun 20094:37 pmRNSHolding(s) in Company
24th Jun 20099:29 amRNSDirector/PDMR Shareholding
23rd Jun 20094:57 pmRNSDirector/PDMR Shareholding
22nd Jun 20098:00 amRNSDirectorate Change
16th Jun 20097:00 amRNSFinal Results
11th May 20097:00 amRNSDirectorate Change
2nd Mar 20098:00 amRNSUpdate on Trading
28th Nov 200810:58 amRNSTotal Voting Rights
25th Nov 20081:52 pmRNSHolding(s) in Company
25th Nov 20081:51 pmRNSHolding(s) in Company
24th Nov 20081:20 pmRNSHolding(s) in Company
24th Nov 20087:00 amRNSInterim Results
20th Nov 20083:32 pmRNSHolding(s) in Company
20th Nov 200812:28 pmRNSHolding(s) in Company
19th Nov 200810:30 amRNSResult of EGM
31st Oct 20087:00 amRNSConfirmation of posting of Circular
30th Oct 20087:30 amRNSNHS Supply Chain Listing
29th Oct 200812:00 pmRNSProposed Placing / Notice of General Meeting
7th Oct 20087:00 amRNSHealthcare Update
30th Sep 200810:46 amRNSTotal Voting Rights
5th Sep 200812:00 pmRNSHolding(s) in Company
1st Sep 200811:14 amRNSDirector/PDMR Shareholding
29th Aug 20089:00 amRNSTotal Voting Rights
21st Aug 200812:37 pmRNSHolding(s) in Company Replace
20th Aug 200812:00 pmRNSHolding(s) in Company
18th Aug 20087:00 amRNSDirector/PDMR Shareholding
6th Aug 200812:18 pmRNSDirector/PDMR Shareholding
31st Jul 20083:09 pmRNSResult of AGM
18th Jul 20087:54 amRNSDirector/PDMR Shareholding
16th Jul 20087:53 amRNSDirector/PDMR Shareholding
8th Jul 20087:00 amRNSDirector/PDMR Shareholding
4th Jul 20083:00 pmRNSAnnual Report and Accounts
3rd Jul 20084:49 pmRNSHolding(s) in Company
2nd Jul 20084:00 pmRNSHolding(s) in Company
27th Jun 20088:50 amRNSHolding(s) in Company
17th Jun 20087:00 amRNSFinal Results
29th May 20081:50 pmRNSResult of Meeting
27th Feb 20087:02 amRNSLatest developments
13th Feb 20088:57 amRNSHolding(s) in Company
5th Feb 20081:19 pmRNSHolding(s) in Company
11th Jan 200812:52 pmRNSHolding(s) in Company
19th Dec 200712:22 pmRNSHolding(s) in Company
29th Nov 20077:01 amRNSInterim Results
28th Sep 200712:02 pmRNSTotal Voting Rights
25th Sep 20073:19 pmRNSHolding(s) in Company
18th Sep 20074:50 pmRNSAdditional Listing
6th Sep 20074:44 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.